DE69826496D1 - RECOMBINANTES IgA - Google Patents

RECOMBINANTES IgA

Info

Publication number
DE69826496D1
DE69826496D1 DE69826496T DE69826496T DE69826496D1 DE 69826496 D1 DE69826496 D1 DE 69826496D1 DE 69826496 T DE69826496 T DE 69826496T DE 69826496 T DE69826496 T DE 69826496T DE 69826496 D1 DE69826496 D1 DE 69826496D1
Authority
DE
Germany
Prior art keywords
disclosed
recombinantes
iga
antibodies
epithelium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69826496T
Other languages
English (en)
Other versions
DE69826496T2 (de
Inventor
Donald Capra
M Hexham
N Carayannopoulos
E Max
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
University of Texas System
Original Assignee
US Department of Health and Human Services
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, University of Texas System filed Critical US Department of Health and Human Services
Publication of DE69826496D1 publication Critical patent/DE69826496D1/de
Application granted granted Critical
Publication of DE69826496T2 publication Critical patent/DE69826496T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69826496T 1997-01-07 1998-01-07 RECOMBINANTES IgA Expired - Fee Related DE69826496T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US779597 1997-01-07
US08/779,597 US6063905A (en) 1997-01-07 1997-01-07 Recombinant human IGA-J. chain dimer
PCT/US1998/000614 WO1998030577A1 (en) 1997-01-07 1998-01-07 RECOMBINANT HUMAN IgA-J. CHAIN DIMER

Publications (2)

Publication Number Publication Date
DE69826496D1 true DE69826496D1 (de) 2004-10-28
DE69826496T2 DE69826496T2 (de) 2005-12-01

Family

ID=25116928

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69826496T Expired - Fee Related DE69826496T2 (de) 1997-01-07 1998-01-07 RECOMBINANTES IgA

Country Status (7)

Country Link
US (2) US6063905A (de)
EP (1) EP1009756B1 (de)
AT (1) ATE277082T1 (de)
AU (1) AU728748B2 (de)
CA (1) CA2278344A1 (de)
DE (1) DE69826496T2 (de)
WO (1) WO1998030577A1 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6045774A (en) * 1997-01-10 2000-04-04 Epicyte Pharmaceutical Inc. J chain polypeptide targeting molecule linked to an imaging agent
WO1998030592A1 (en) 1997-01-10 1998-07-16 Epicyte Pharmaceutical, Inc. Novel epithelial tissue targeting agent
US6911204B2 (en) 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
WO2002013861A2 (en) * 2000-08-11 2002-02-21 Favrille, Inc. Method and composition for altering a t cell mediated pathology
US6932967B2 (en) * 2001-03-22 2005-08-23 Michael R. Simon Human medical treatment by aerosol inhalation of immunoglobulin A
US20030118585A1 (en) * 2001-10-17 2003-06-26 Agy Therapeutics Use of protein biomolecular targets in the treatment and visualization of brain tumors
US7291477B2 (en) 2001-07-03 2007-11-06 Xenotope Diagnostics, Inc. Method and device for trichomonas detection
US20060165675A1 (en) * 2002-08-02 2006-07-27 Richman-Eisenstat Janice Beth Modulation of mesenchymal cells via iga-receptors
US20050014932A1 (en) * 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
US8394379B2 (en) * 2003-05-15 2013-03-12 Iogenetics, Llc Targeted cryptosporidium biocides
US8703134B2 (en) 2003-05-15 2014-04-22 Iogenetics, Llc Targeted cryptosporidium biocides
US7566447B2 (en) 2003-05-15 2009-07-28 Iogenetics, Llc Biocides
US7700097B2 (en) * 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
WO2005030931A2 (en) * 2003-09-23 2005-04-07 Favrille, Inc. Altering a b cell pathology using self-derived antigens in conjunction with specific-binding cytoreductive agent
US7750123B2 (en) * 2003-11-25 2010-07-06 Dana Farber Cancer Institute, Inc. Antibodies against SARS-CoV and methods of use thereof
WO2006132665A2 (en) * 2004-10-20 2006-12-14 Iogenetics, Llc Biocides
KR101370253B1 (ko) * 2004-10-22 2014-03-05 암젠 인크 재조합 항체의 재접힘 방법
WO2006074399A2 (en) * 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
US8017103B2 (en) * 2005-07-01 2011-09-13 Board Of Regents, The University Of Texas System Methods and compositions to diagnose trichomonas infection
US20070015224A1 (en) * 2005-07-01 2007-01-18 Board Of Regents, The University Of Texas System Methods and compositions to diagnose Trichomonas infection
US7439028B2 (en) * 2005-09-30 2008-10-21 Board Of Regents, The University Of Texas System Methods and compositions to correlate Trichomonas infection with prostate cancer
US7803567B2 (en) * 2005-12-09 2010-09-28 Board Of Regents, The University Of Texas System Methods and compositions for detecting trichomonas in a sample contacted with fixative
US8481023B2 (en) * 2006-09-15 2013-07-09 Ottawa Hospital Research Institute Oncolytic rhabdovirus
AU2008298904B2 (en) * 2007-09-14 2014-10-16 Amgen Inc. Homogeneous antibody populations
CA2793959C (en) 2010-03-25 2019-06-04 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
SI2691530T1 (en) 2011-06-10 2018-08-31 Oregon Health & Science University CMV glycoproteins and recombinant vectors
US20130189754A1 (en) 2011-09-12 2013-07-25 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing hiv-1 proteins by broadly neutralizing antibodies
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20160039913A1 (en) * 2012-09-10 2016-02-11 Lfb Usa, Inc. The use of antibodies in treating hiv infection and suppressing hiv transmission
BR112015019348A2 (pt) 2013-02-13 2017-08-22 Lab Francais Du Fractionnement Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária
EP2956480B1 (de) 2013-02-13 2019-09-04 Laboratoire Français du Fractionnement et des Biotechnologies In hohem masse galactosylierte anti-tnf-alpha-antikörper und verwendungen davon
EP2848937A1 (de) 2013-09-05 2015-03-18 International Aids Vaccine Initiative Verfahren zur Identifizierung neuartiger HIV-1-Immunogene
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US10925962B2 (en) * 2014-07-18 2021-02-23 Nippi, Incorporated Polymeric IgA-type recombinant antibody and use thereof
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
AU2016238246B2 (en) 2015-03-25 2021-05-13 Igm Biosciences, Inc. Multi-valent hepatitis B virus antigen binding molecules and uses thereof
US10279031B2 (en) 2016-05-11 2019-05-07 Phibro Animal Health Corporation Composition comprising antigens and a mucosal adjuvant and a method for using
EP4226162A1 (de) * 2020-10-06 2023-08-16 Macfarlane Burnet Institute for Medical Research and Public Health Limited Verfahren und zusammensetzungen auf der basis von längsstudien

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698679A (en) * 1994-09-19 1997-12-16 National Jewish Center For Immunology And Respiratory Medicine Product and process for targeting an immune response

Also Published As

Publication number Publication date
US6673342B1 (en) 2004-01-06
ATE277082T1 (de) 2004-10-15
AU728748B2 (en) 2001-01-18
AU5915498A (en) 1998-08-03
EP1009756A1 (de) 2000-06-21
EP1009756A4 (de) 2001-11-21
WO1998030577A1 (en) 1998-07-16
DE69826496T2 (de) 2005-12-01
EP1009756B1 (de) 2004-09-22
US6063905A (en) 2000-05-16
CA2278344A1 (en) 1998-07-16

Similar Documents

Publication Publication Date Title
DE69826496D1 (de) RECOMBINANTES IgA
AU1593001A (en) Recombinant gelatin in vaccines
NZ592550A (en) Compostion comprising antibody capable of binding to p40 subunit of IL-12
ATE328068T1 (de) Papillomavirus vakzine
DK0760848T3 (da) Lactobacillusstammer af menneskelig oprindelse, deres sammensætninger og anvendelse deraf
PL339735A1 (en) Pappiloma virus capsomer vaccine compositions and methods of applying them
IT1261949B (it) Composizione terapeutica a base di interferone umano, impiego di interferone umano in tale composizione e relativo metodo.
IL148079A0 (en) Human ctla-4 antibodies and compositions containing the same
WO1999033868A3 (en) Human papillomavirus vaccine
RS51157B (sr) Baff receptor (bcma), imunoregulatorni agens
DK1137430T3 (da) Terapeutikum til undertrykkelse af snorkelyde
CY1107351T1 (el) Καινοφανης μεταλλαγμενη μορφη απιμινασης αργινινης
DK0675733T3 (da) Peptid-carbohydrat-konjugater, der genererer T-celleimmunitet
AU2002220460A1 (en) The polypeptide fragments of hepatitis e virus, the vaccine composition comprising said fragments and the diagnostic kits
DE69919984D1 (de) Interleukin-12 und herpes simplex virusantigen enthaltende impfstoffe
WO2001040473A3 (en) Pseudomonas aeruginosa antigens
AU4985596A (en) Novel aroylaniline derivatives, compositions and uses thereof in the treatment of viral infections
DE69736779D1 (de) Zusammensetzungen von rekombinanten papillomavirus vakzinen
ATE283066T1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
FI946076A (fi) Modifioituja Kluyveromyces-hiivoja, valmistus ja käyttö
WO2000042987A3 (en) Targeted vesicular constructs for cytoprotection and treatment of h. pylori infections
SI1173194T1 (en) Recombinant sp-a for the treatment or prevention of pulmonary infection and inflammation
AU2002229850A1 (en) Polypeptide inducing hiv-neutralising antibodies
NO982151L (no) Hemoregulatoriske forbindelser
UA49450A (uk) Вакцина інактивована рекомбінантна проти інфекційного ринотрахеїту великої рогатої худоби

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee